Table 2 |
|
|
Regulatory T cells in human systemic lupus erythematosus |
|
| Regulatory T cell subset |
Comment |
|
|
|
| CD4+CD25+ cells |
|
| Decreased [42-45] |
|
| CD4+CD25high cells |
Inverse correlation with lupus activity [44,47,49,50,52] |
| Decreased [22,46-52] |
|
| Similar to healthy donors [57,58,65] |
|
| Increase with treatment and disease improvement |
|
| Corticosteroids [53] |
|
| Plasmapheresis [54] |
|
| Rituximab [55,56] |
|
| CD4+Foxp3+ cells |
|
| Decreased [46,48,50] |
Inverse correlation with disease activity [46,48,50] |
| Similar to healthy donors [57] |
|
| Increased [47,61-63] |
Positive correlation with disease activity [47,61-63] |
| Suppressive activity in vitro |
|
| Decreased [48,50,57,62] (one-third of patients [60]) |
Decrease largely due to IFNγ released by patient antigen-presenting cells [62] |
| Not decreased [49] |
Decreased due to resistance of systemic lupus erythematosus responder or accessory
cells [57] |
|
|
|
|
Horwitz Arthritis Research & Therapy 2008 10:227 doi:10.1186/ar2511 |
|